2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 275-277
Transcriptional and epigenetic remodelling orchestrate immune evasion and create therapeutic vulnerabilities in lymphoid malignancies, by providing lineage platicity and competitive fitness, inducing extracellular vesicles secretion to modulate the immune microenvironment, downregulating endogenous retroelements, and reorganizing enhancer condensates.
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Pediatric, Animal Model
PAPER

45 IKZF1 alterations drive immune microenvironment remodeling in BCR::ABL1-positive acute lymphoblastic leukemia (BCR::ABL1 ALL)

Chun Shik Park, PhD, Hao Shi2, Wan Changxin3, Ilaria Iacobucci, PhD4, Prady Baviskar, PhD, DVM5, Stephanie Hayes6, Zuo-Fei Yuan7, Long Wu8, Vishwajeeth Pagala9, Kiran Kodali10, Wei Wang11, Anthony A High12, Woo Jung Cho13, Paolo Neviani14, Yunchao Chang, PhD15, Xiaoming Zhong, PhD16, Yiming Wu17, Lindsey Elizabeth Montefiori, PhD18, Pooja Singh19, Meenasri Kumbaji20, Ruth G Tatevossian, PhD, MBBS21, Camenzind G Robinson22, Laura Janke23, Kathryn G. Roberts, PhD24, Hongbo Chi, PhD25, Charles G. Mullighan, MBBS (Hons), MSc, MD26
1 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
2 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
3 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
4 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
5 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
6 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
7 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
8 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
9 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
10 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
11 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
12 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
13 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
14 Children’s Hospital Los Angeles, Los Angeles, California, United States
15 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
16 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
17 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
18 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
19 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
20 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
21 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
22 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
23 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
24 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
25 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
26 St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Introduction: IKZF1, encoding the lymphoid transcription factor IKAROS, is frequently altered in BCR::ABL1 ALL and is associated with poor outcome with conventional chemotherapy and immunotherapy-based regimens. We previously demonstrated (PMID 26321221) that IKZF1 alterations enhance leukemic cell adhesion and mislocalization in the tumor microenvironment (TME), promoting treatment resistance. We hypothesized that IKZF1 alterations promote an immunosuppressive TME and resistance to immunotherapy.

Methods: We generated a mouse model harboring a conditional deletion of Ikzf1 exons 4–7 (Ikzf1flox[E4-E7]/+) that recapitulates the most common IKZF1 deletion in BCR::ABL1 ALL and that encodes the dominant negative isoform, IK6. Transduction of bone marrow (BM) cells with a retrovirus encoding BCR::ABL1-Cre generated BCR::ABL1;IK6 (IK6) leukemia cells. Transplantation into immunocompetent mice established a model in which IKZF1-altered leukemic cells interact with an intact immune and stromal microenvironment. We analyzed the impact of IKZF1 alteration on TME by single-cell RNA-seq (scRNA-seq), Xenium spatial transcriptomics, flow cytometry, and proteomic analysis. We profiled 18 human BCR::ABL1 ALL samples by scRNA-seq/CITE-seq.

Results: Mice transplanted with IK6 leukemia cells exhibited greater disease penetrance and shorter latency than those transplanted with BCR::ABL1;IKZF1 wild-type (IK1) leukemia cells. To define the impact of IKZF1 alteration on the TME, we performed scRNA-seq of leukemias arising in immunocompetent mice. IK6 leukemias exhibited increased CD8+ T-cell exhaustion, elevated PD-L1+ macrophages, and expansion of pro-/immature neutrophils. Consistent with these findings, scRNA-seq/CITE-seq analysis of human BCR::ABL1 ALL samples with IKZF1 alterations demonstrated enhanced CD8+ T-cell exhaustion, along with additional immune dysregulation characterized by reduced central memory and effector memory CD8+ T-cell subsets.

Xenium spatial transcriptomics using a customized 292-gene panel also validated that IK6 promotes CD8⁺ T-cell exhaustion and expansion of pro-/immature neutrophils. CellCharter analysis revealed reduced interaction of IK6 leukemic cells with antitumor T cells. IK6 leukemias were also associated with enrichment of PD-L1-high immune cell populations, despite reduced PD-L1 expression in leukemic cells. Consistently, flow cytometry showed increased PD-L1 protein expression on multiple immune cell populations, whereas PD-L1 expression was lower on IK6 leukemic cells than on IK1 leukemic cells.

Given the immunosuppressive role of exosomal PD-L1 and the ability of extracellular vesicles (EVs) to mediate intercellular communication, we investigated whether tumor-derived EVs contribute to TME remodeling in IK6 leukemia. Following transplantation of PalmGRET-labeled (EV reporter) IK1 and IK6 leukemia cells into immunocompetent mice, we observed increased transfer of tumor-derived EVs to multiple immune cell populations in IK6 leukemia. EVs from IK6-bearing mice contained higher levels of PD-L1 and TGF-β, indicating enhanced immunosuppressive potential. We found that IK6 leukemia cells secreted larger EVs. Transcriptomic analysis of EVs revealed enrichment of Cd19, Cd274 (PD-L1), and transcripts encoding cell-surface and adhesion molecules, in IK6 EVs. Proteomic profiling similarly demonstrated enrichment of CD19, PD-L1 and membrane-associated adhesion proteins in IK6-derived EVs. Strikingly, IK6 also mediated higher BCR::ABL1 expression across multiple immune cell types. Together, these findings indicate that IKZF1 alterations remodel EV cargo composition and enhance EV-mediated immunosuppressive signaling within the leukemia microenvironment.

Finally, we investigated whether IK6 affects blinatumomab efficacy, as IKZF1 alterations are associated with increased CD8⁺ T-cell exhaustion. Indeed, IK6 exhibited reduced blinatumomab-mediated killing of leukemic cells and diminished number of humanized CD3 T cells in vitro in human CD19-transduced BCR::ABL1-positive murine leukemia cells co-cultured with CD3/CD28 bead-activated humanized CD3 T cells.

Conclusions: Collectively, our findings demonstrate that IKZF1 alterations in leukemic cells promote leukemogenesis and disease progression in immunocompetent mice through inside-out signaling that perturbs multiple immune cell populations, in part via EV-mediated signaling. This EV-mediated signaling may contribute to resistance to therapy.

Chun Shik Park, PhD: No relevant conflicts of interest to declare.